27563235|t|Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor - targeted cancer therapy
27563235|a|Fibroblast growth factor receptors (FGFRs) are attractive candidate cancer therapy targets as they are overexpressed in multiple types of tumors, such as breast, prostate, bladder, and lung cancer. In this study, a natural ligand of FGFR, an engineered variant of fibroblast growth factor 1 (FGF1V), was conjugated to a potent cytotoxic drug, monomethyl auristatin E (MMAE), and used as a targeting agent for cancer cells overexpressing FGFRs, similar to antibodies in antibody-drug conjugates. The FGF1V-valine-citrulline-MMAE conjugate showed a favorable stability profile, bound FGFRs on the cell surface specifically, and efficiently released the drug (MMAE) upon cleavage by the lysosomal protease cathepsin B. Importantly, the conjugate showed a prominent cytotoxic effect toward cell lines expressing FGFR. FGF1V-vcMMAE was highly cytotoxic at concentrations even an order of magnitude lower than those found for free MMAE. This effect was FGFR -specific as cells lacking FGFR did not show any increased mortality.
27563235	0	6	Design	T052	C1707689
27563235	11	26	characteristics	T080	C1521970
27563235	30	39	cytotoxic	T169	C1511636
27563235	40	66	fibroblast growth factor 1	T116,T123	C0079349
27563235	67	76	conjugate	T121	C1254351
27563235	81	114	fibroblast growth factor receptor	T116,T192	C0060369
27563235	117	140	targeted cancer therapy	T061	C3854476
27563235	141	175	Fibroblast growth factor receptors	T116,T192	C0060369
27563235	177	182	FGFRs	T116,T192	C0060369
27563235	209	223	cancer therapy	T061	C0920425
27563235	224	231	targets	T169	C1521840
27563235	244	257	overexpressed	T045	C1514559
27563235	261	269	multiple	T081	C0439064
27563235	279	285	tumors	T191	C0027651
27563235	295	301	breast	T191	C1458155
27563235	303	311	prostate	T191	C0033578
27563235	313	320	bladder	T191	C0005695
27563235	326	337	lung cancer	T191	C0242379
27563235	356	370	natural ligand	T044	C1749457
27563235	374	378	FGFR	T116,T192	C0060369
27563235	383	401	engineered variant	T116	C0034861
27563235	405	431	fibroblast growth factor 1	T116,T123	C0079349
27563235	433	438	FGF1V	T116,T123	C0079349
27563235	445	455	conjugated	T082	C0522529
27563235	461	482	potent cytotoxic drug	T121	C0304497
27563235	484	507	monomethyl auristatin E	T116,T121	C1565020
27563235	509	513	MMAE	T116,T121	C1565020
27563235	530	545	targeting agent	T043	C0599894
27563235	550	562	cancer cells	T025	C0334227
27563235	563	577	overexpressing	T045	C1514559
27563235	578	583	FGFRs	T116,T192	C0060369
27563235	596	606	antibodies	T116,T129	C0003241
27563235	610	634	antibody-drug conjugates	T061	C2346828
27563235	640	678	FGF1V-valine-citrulline-MMAE conjugate	T121	C1254351
27563235	698	715	stability profile	T044	C1327386
27563235	717	722	bound	T044	C1167622
27563235	723	728	FGFRs	T116,T192	C0060369
27563235	736	748	cell surface	T026	C0699040
27563235	749	761	specifically	T080	C0205369
27563235	767	778	efficiently	T080	C0442799
27563235	779	787	released	T169	C1283071
27563235	792	803	drug (MMAE)	T116,T121	C1565020
27563235	809	817	cleavage	T044	C0597304
27563235	825	855	lysosomal protease cathepsin B	T116,T126	C0699919
27563235	874	883	conjugate	T121	C1254351
27563235	893	902	prominent	T080	C0205402
27563235	903	919	cytotoxic effect	T049	C0596402
27563235	927	937	cell lines	T025	C0334227
27563235	938	948	expressing	T045	C0597360
27563235	949	953	FGFR	T116,T192	C0060369
27563235	955	967	FGF1V-vcMMAE	T121	C1254351
27563235	979	988	cytotoxic	T169	C1511636
27563235	992	1006	concentrations	T081	C1446561
27563235	1034	1039	lower	T052	C2003888
27563235	1066	1070	MMAE	T116,T121	C1565020
27563235	1088	1092	FGFR	T116,T192	C0060369
27563235	1106	1111	cells	T025	C0334227
27563235	1112	1119	lacking	T080	C0332268
27563235	1120	1124	FGFR	T116,T192	C0060369
27563235	1125	1137	did not show	T033	C1513916
27563235	1142	1151	increased	T081	C0205217
27563235	1152	1161	mortality	T043	C0007587